{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:05Z","timestamp":1789506665894,"version":"build-2803163510"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128779","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T10:10:19Z","timestamp":1780740619000},"page":"128779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Decoding yellow fever virus immunogenicity: Targeting highly effective epitopes of YFV for next-generation vaccine design"],"prefix":"10.1016","volume":"88","author":[{"given":"Victor Hugo","family":"Aquino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Leticia","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128779_bb0005","author":"Pan American Health Organization \/ World Health Organization"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128779_bb0010","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1086\/511869","article-title":"Yellow fever: epidemiology and prevention","volume":"44","author":"Barnett","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128779_bb0015","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/trstmh\/tru092","article-title":"The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases","volume":"108","author":"Johansson","year":"2014","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128779_bb0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1590\/1806-9282.64.02.106","article-title":"Yellow fever","volume":"64","author":"Litvoc","year":"2018","journal-title":"Rev Assoc M\u00e9dica Bras"},{"key":"10.1016\/j.vaccine.2026.128779_bb0025","author":"World Health Organization"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128779_bb0030","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1473-3099(16)30513-8","article-title":"Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015\u201316: a modelling study","volume":"17","author":"Kraemer","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128779_bb0035","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.tim.2018.05.012","article-title":"Yellow fever virus: knowledge gaps impeding the fight against an old foe","volume":"26","author":"Douam","year":"2018","journal-title":"Trends Microbiol"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128779_bb0040","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S1473-3099(17)30419-X","article-title":"Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis","volume":"17","author":"Shearer","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128779_bb0045","series-title":"WHO Vaccine Management Handbook Module VMH-E2","author":"World Health Organization","year":"2015"},{"issue":"RR-7","key":"10.1016\/j.vaccine.2026.128779_bb0050","first-page":"1","article-title":"Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2026.128779_bb0055","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J Clin Virol"},{"issue":"20","key":"10.1016\/j.vaccine.2026.128779_bb0060","first-page":"201","article-title":"Meeting of the strategic advisory group of experts on immunization, April 2013 \u2013 conclusions and recommendations","volume":"88","author":"World Health Organization","year":"2013","journal-title":"Releve Epidemiol Hebd"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128779_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005625","article-title":"Contemporary status of insecticide resistance in the major Aedes vectors of arboviruses infecting humans","volume":"11","author":"Moyes","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128779_bb0070","first-page":"193","article-title":"Eliminate yellow fever epidemics (EYE): a global strategy, 2017\u20132026","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2026.128779_bb0075","series-title":"Fields Virology","first-page":"712","article-title":"Flaviviridae","author":"Lindenbach","year":"2013"},{"key":"10.1016\/j.vaccine.2026.128779_bb0080","series-title":"Advances in virus research","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0065-3527(03)59003-0","article-title":"Flavivirus structure and membrane fusion","author":"Heinz","year":"2003"},{"issue":"6529","key":"10.1016\/j.vaccine.2026.128779_bb0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/375291a0","article-title":"The envelope glycoprotein from tick-borne encephalitis virus at 2 \u00c5 resolution","volume":"375","author":"Rey","year":"1995","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128779_bb0090","doi-asserted-by":"crossref","first-page":"206","DOI":"10.15252\/embr.201745302","article-title":"The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design","volume":"19","author":"Rey","year":"2018","journal-title":"EMBO Rep"},{"issue":"7614","key":"10.1016\/j.vaccine.2026.128779_bb0095","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nature18938","article-title":"Structural basis of potent Zika\u2013dengue virus antibody cross-neutralization","volume":"536","author":"Barba-Spaeth","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128779_bb0100","doi-asserted-by":"crossref","DOI":"10.1007\/s11908-017-0566-9","article-title":"Live attenuated yellow fever 17D vaccine: a legacy vaccine still controlling outbreaks in modern day","volume":"19","author":"Collins","year":"2017","journal-title":"Curr Infect Dis Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128779_bb0105","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.immuni.2010.10.006","article-title":"Systems vaccinology","volume":"33","author":"Pulendran","year":"2010","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128779_bb0110","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.chom.2009.04.001","article-title":"Pathogenesis of Flavivirus infections: using and abusing the host cell","volume":"5","author":"Fernandez-Garcia","year":"2009","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/viro.2001.1232","article-title":"Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus","volume":"292","author":"Germi","year":"2002","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128779_bb0120","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3389\/fimmu.2018.02180","article-title":"Flavivirus receptors: diversity, identity, and cell entry","volume":"26","author":"Laureti","year":"2018","journal-title":"Front Immunol"},{"issue":"8095","key":"10.1016\/j.vaccine.2026.128779_bb0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-025-09689-2","article-title":"Multiple LDLR family members act as entry receptors for yellow fever virus","volume":"649","author":"Chong","year":"2026","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/v6010069","article-title":"Flavivirus entry receptors: an update","volume":"6","author":"Perera-Lecoin","year":"2013","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128779_bb0135","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrmicro3469","article-title":"Viral apoptotic mimicry","volume":"13","author":"Amara","year":"2015","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128779_bb0140","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nsmb.1456","article-title":"Viral membrane fusion","volume":"15","author":"Harrison","year":"2008","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128779_bb0145","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0955-0674(03)00081-4","article-title":"Insider information: what viruses tell us about endocytosis","volume":"15","author":"Pelkmans","year":"2003","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.vaccine.2026.128779_bb0150","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00467-20","article-title":"A sensitive yellow fever virus entry reporter identifies valosin-containing protein (VCP\/p97) as an essential host factor for flavivirus uncoating","author":"Ramanathan","year":"2020","journal-title":"mBio"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128779_bb0155","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJMp058263","article-title":"Control of Japanese encephalitis \u2014 within our grasp?","volume":"355","author":"Solomon","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128779_bb0160","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/erv.11.7","article-title":"New Japanese encephalitis vaccines: alternatives to production in mouse brain","volume":"10","author":"Halstead","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128779_bb0165","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4161\/hv.26902","article-title":"Japanese encephalitis: the virus and vaccines","volume":"10","author":"Yun","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128779_bb0170","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S1473-3099(19)30323-8","article-title":"Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study","volume":"19","author":"Domingo","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128779_bb0175","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3389\/fimmu.2019.02192","article-title":"Short-lived immunity after 17DD yellow fever single dose indicates that booster vaccination may be required to guarantee protective immunity in children","volume":"26","author":"Campi-Azevedo","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128779_bb0180","doi-asserted-by":"crossref","first-page":"733","DOI":"10.12688\/wellcomeopenres.23138.1","article-title":"Booster vaccination against yellow fever in Gambian children-(BoVY) -a phase 3 clinical trial to establish safety and immunogenicity of repeated YF vaccination in healthy Gambian children of different ages","volume":"24","author":"Kampmann","year":"2024","journal-title":"Wellcome Open Res"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128779_bb0185","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1084\/jem.65.6.767","article-title":"The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus","volume":"65","author":"Theiler","year":"1937","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128779_bb0190","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1084\/jem.65.6.787","article-title":"The use of yellow fever virus modified by in vitro cultivation for human immunization","volume":"65","author":"Theiler","year":"1937","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2026.128779_bb0195","series-title":"Yellow fever","author":"Strode","year":"1951"},{"issue":"23","key":"10.1016\/j.vaccine.2026.128779_bb0200","first-page":"647","article-title":"Centers for Disease Control and Prevention (CDC). Yellow fever vaccine booster doses: recommendations of the advisory committee on immunization practices, 2015","volume":"64","author":"Staples","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128779_bb0205","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coi.2009.05.018","article-title":"Yellow fever vaccine \u2014 how does it work and why do rare cases of serious adverse events take place?","volume":"21","author":"Barrett","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128779_bb0210","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/hv.1.5.2221","article-title":"Yellow fever 17D vaccine safety and immunogenicity in the elderly","volume":"1","author":"Monath","year":"2005","journal-title":"Hum Vaccin"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128779_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149871","article-title":"A Single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination","volume":"11","author":"Wieten","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0220","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128779_bb0225","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1084\/jem.20082292","article-title":"Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses","volume":"205","author":"Gaucher","year":"2008","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128779_bb0230","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","article-title":"The yellow fever virus vaccine induces a broad and Polyfunctional human memory CD8+ T cell response","volume":"183","author":"Akondy","year":"2009","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128779_bb0235","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3390\/ph14090891","article-title":"The present and future of yellow fever vaccines","volume":"14","author":"Hansen","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128779_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027753","article-title":"Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study","volume":"6","author":"Roukens","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128779_bb0245","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taac095","article-title":"Yellow fever vaccine safety in immunocompromised individuals: a systematic review and meta-analysis","volume":"30","author":"Wigg De Ara\u00fajo Lagos","year":"2023","journal-title":"J Travel Med"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128779_bb0250","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00251-010-0461-0","article-title":"The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques\u2014implications for recombinant vaccine design","volume":"62","author":"Mudd","year":"2010","journal-title":"Immunogenetics"},{"issue":"282","key":"10.1016\/j.vaccine.2026.128779_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa3700","article-title":"Long-lasting stem cell\u2013like memory CD8+ T cells with a na\u00efve-like profile upon yellow fever vaccination","volume":"7","author":"Fuertes Marraco","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128779_bb0260","first-page":"2150","article-title":"Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response","volume":"190","author":"Blom","year":"1950","journal-title":"J Immunol Baltim Md"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128779_bb0265","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","article-title":"Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines","volume":"28","author":"Miller","year":"2008","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128779_bb0270","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3389\/fimmu.2020.01836","article-title":"A systematic, unbiased mapping of CD8+ and CD4+ T cell epitopes in yellow fever Vaccinees","volume":"31","author":"Stryhn","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0275","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1006\/viro.2001.1255","article-title":"Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E","volume":"293","author":"Co","year":"2002","journal-title":"Virology"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128779_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026494","article-title":"Human leukocyte antigen (HLA) class I restricted epitope discovery in yellow fewer and dengue viruses: importance of HLA binding strength","volume":"6","author":"Lund","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128779_bb0285","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10875-008-9267-3","article-title":"Human immune memory to yellow fever and smallpox vaccination","volume":"29","author":"Wrammert","year":"2009","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2026.128779_bb0290","series-title":"Crossroads between Innate and Adaptive Immunity","article-title":"Understanding the role of innate immunity in the mechanism of action of the live attenuated yellow fever vaccine 17D","author":"Querec","year":"2007"},{"issue":"23","key":"10.1016\/j.vaccine.2026.128779_bb0295","doi-asserted-by":"crossref","first-page":"12794","DOI":"10.1128\/JVI.01160-13","article-title":"Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins","volume":"87","author":"James","year":"2013","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001938","article-title":"T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II Binding Motifs","volume":"7","author":"De Melo","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0305","doi-asserted-by":"crossref","first-page":"8907","DOI":"10.1038\/s41598-017-09331-w","article-title":"Protein structure shapes immunodominance in the CD4 T cell response to yellow fever vaccination","volume":"7","author":"Koblischke","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128779_bb0310","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3390\/v12111300","article-title":"Identification of novel yellow fever class II epitopes in YF-17D Vaccinees","volume":"12","author":"Mateus","year":"2020","journal-title":"Viruses"},{"issue":"7685","key":"10.1016\/j.vaccine.2026.128779_bb0315","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature24633","article-title":"Origin and differentiation of human memory CD8 T cells after vaccination","volume":"552","author":"Akondy","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128779_bb0320","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/icb.2010.155","article-title":"Insights into human CD8+ T-cell memory using the yellow fever and smallpox vaccines","volume":"89","author":"Ahmed","year":"2011","journal-title":"Immunol Cell Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128779_bb0325","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1084\/jem.20091738","article-title":"IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses","volume":"207","author":"Linterman","year":"2010","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0330","doi-asserted-by":"crossref","DOI":"10.1128\/MMBR.00055-16","article-title":"The antigenic structure of Zika virus and its relation to other flaviviruses: implications for infection and immunoprophylaxis","volume":"81","author":"Heinz","year":"2017","journal-title":"Microbiol Mol Biol Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0335","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/vim.2019.0107","article-title":"Structure\u2013function of the yellow fever virus envelope protein: analysis of antibody epitopes","volume":"33","author":"Davis","year":"2020","journal-title":"Viral Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128779_bb0340","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/iub.1556","article-title":"Molecular basis of antibody-mediated neutralization and protection against flavivirus","volume":"68","author":"Dai","year":"2016","journal-title":"IUBMB Life"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128779_bb0345","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.virol.2010.12.020","article-title":"Antibody-mediated neutralization of flaviviruses: a reductionist view","volume":"411","author":"Dowd","year":"2011","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128779_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003458","article-title":"Dissection of antibody specificities induced by yellow fever vaccination","volume":"9","author":"Vratskikh","year":"2013","journal-title":"PLoS Pathog"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128779_bb0355","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1073\/pnas.1921388117","article-title":"Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine","volume":"117","author":"Wec","year":"2020","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0360","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41541-025-01302-x","article-title":"Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms","volume":"10","author":"Pineda-Pe\u00f1a","year":"2025","journal-title":"Npj Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0365","doi-asserted-by":"crossref","DOI":"10.4110\/in.2024.24.e8","article-title":"Cytokines in follicular helper T cell biology in physiologic and pathologic conditions","volume":"24","author":"Choi","year":"2024","journal-title":"Immune Netw"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128779_bb0370","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3389\/fimmu.2019.01787","article-title":"Remembrance of things past: long-term B cell memory after infection and vaccination","volume":"31","author":"Palm","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0375","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0042-6822(89)90509-6","article-title":"Synthetic peptides derived from the deduced amino acid sequence of the E-glycoprotein of Murray Valley encephalitis virus elicit antiviral antibody","volume":"171","author":"Roehrig","year":"1989","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0380","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0042-6822(83)90059-4","article-title":"Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein","volume":"125","author":"Schlesinger","year":"1983","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2026.128779_bb0385","series-title":"Advances in virus research","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0065-3527(08)60263-8","article-title":"Epitope mapping of Flavivirus glycoproteins","author":"Heinz","year":"1986"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128779_bb0390","article-title":"Linear and continuous Flavivirus epitopes from naturally infected humans","volume":"12","author":"Fumagalli","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128779_bb0395","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3390\/v14081645","article-title":"Mapping and validation of peptides differentially recognized by antibodies from the serum of yellow fever virus-infected or 17DD-vaccinated patients","volume":"14","author":"Oliveira","year":"2022","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0400","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1038\/s41598-024-60680-9","article-title":"Advancing molecular modeling and reverse vaccinology in broad-spectrum yellow fever virus vaccine development","volume":"14","author":"Da Silva","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0405","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s43141-023-00621-7","article-title":"Exploring structural antigens of yellow fever virus to design multi-epitope subunit vaccine candidate by utilizing an immuno-informatics approach","volume":"21","author":"Sura","year":"2023","journal-title":"J Genet Eng Biotechnol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128779_bb0410","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/07391102.2019.1707120","article-title":"Multi-epitope based vaccine against yellow fever virus applying immunoinformatics approaches","volume":"39","author":"Tosta","year":"2021","journal-title":"J Biomol Struct Dyn"},{"issue":"D1","key":"10.1016\/j.vaccine.2026.128779_bb0415","doi-asserted-by":"crossref","first-page":"D339","DOI":"10.1093\/nar\/gky1006","article-title":"The immune epitope database (IEDB): 2018 update","volume":"47","author":"Vita","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"10.1016\/j.vaccine.2026.128779_bb0420","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128779_bb0425","article-title":"DiscoTope-3.0: improved B-cell epitope prediction using inverse folding latent representations","volume":"8","author":"H\u00f8ie","year":"2024","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128779_bb0430","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1080\/07391102.2021.2024253","article-title":"Modeling mRNA-based vaccine YFV.E1988 against yellow fever virus E-protein using immuno-informatics and reverse vaccinology approach","volume":"41","author":"Khan","year":"2023","journal-title":"J Biomol Struct Dyn"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128779_bb0435","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00089-20","article-title":"T cell responses induced by attenuated Flavivirus vaccination are specific and show limited cross-reactivity with other Flavivirus species. L\u00f3pez S, editor","volume":"94","author":"Grifoni","year":"2020","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128779_bb0440","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/nbt.3662","article-title":"Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes","volume":"34","author":"Bentzen","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128779_bb0445","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41596-019-0133-y","article-title":"Mass spectrometry\u2013based identification of MHC-bound peptides for immunopeptidomics","volume":"14","author":"Purcell","year":"2019","journal-title":"Nat Protoc"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:35:36Z","timestamp":1789504536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26005888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":89,"alternative-id":["S0264410X26005888"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128779","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decoding yellow fever virus immunogenicity: Targeting highly effective epitopes of YFV for next-generation vaccine design","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128779"}}